These 28 biotech startups have attracted the most VC cash, making them prime candidates for an acquisition or IPO
Venture-capital money flowing into biotech over the past few years has led to record levels of private financing, according to a new analysis by Jefferies analyst Michael Yee and his team. Based on industry trends, companies with funding rounds in the past two years could go public next year or in 2021, they said. Those companies could be targets for M&A. Read on to see the companies with the top 30 fundraising rounds in that time, which could be IPO candidates or M&A targets. Click here for more BI Prime stories.
It's a good time to be a private biotech company. Venture-capital funds have been flowing into the industry, prompting record levels of private biotech financings, according to a new analysis from Jefferies analyst Michael Yee and his team. A large crop of those private companies could be set to go public in 2020 or 2021, or could even get acquired, Yee and team said. "It will also be interesting to see how many of these may lead to M&A instead of IPOs," the Jefferies analysts said. In the past few months, two private biotechs, cancer drugmaker Peloton Therapeutics and cell-therapy company BlueRock Therapeutics, were both sold to big pharma companies. Being a biotech company in the business of developing drugs is notoriously risky and expensive. Ballooning capital needs can propel biotechs to either go public or sell themselves before they're even selling a single drug. The Jefferies team's predictions are rooted in what happened in 2017, when private financings gave momentum to a wave of IPOs in 2018 and 2019. Since then, the financing trend has expanded, with 40 to 60 private rounds being announced each quarter, an increase from 20 to 30 rounds per quarter in 2017, their analysis found. Read more: These 10 buzzy digital health startups are poised to go public in the next year Yee and team say this trend reflects the overall strength of VC funds, with large amounts of capital flowing into them and then out to startups. The market has also been strong for biotech companies since the sequencing of the human genome in the early 2000s, and especially since the passage of the landmark healthcare law the Affordable Care Act in 2010, they said. Well-funded VCs are betting heavily on biotechs based on factors like management teams and innovative ideas, but they're also underestimating how much risk is in the mix, Wedbush analyst David Nierengarten told Business Insider. "I have seen this trend before and it ends poorly," he said. The Jefferies analysis, which was released in mid-August, took a look at the top 30 fundraising rounds between May 2017 and August 2019. Since it was posted, two of the companies it tapped have said that they plan to go public. Read on to for more about the biotechs that made the cut.28. SpringWorks Therapeutics
Round size and year: $125 million in 2019 More about SpringWorks Therapeutics: Pfizer launched this spinoff biopharmaceutical startup in 2017. The company's furthest-along drug is nirogacestat, which is intended for desmoid tumors, a rare tumor type that has no FDA-approved treatments. The drug is being studied in late-stage research. The biotech's latest funding round was led by the hedge fund Perceptive Advisors. Some other key investors were Pfizer Ventures, British drugmaker GlaxoSmithKline, and Bain Capital. The funding will be used to move nirogacestat and another drug for rare cancers forward, potentially towards FDA approvals and commercial sale, SpringWorks Therapeutics said. 27. Compass Therapeutics
Round size and year: $132 million in 2018 More about Compass Therapeutics: The biotech company makes drugs intended to engage the human immune system and fend off diseases like cancer, inflammatory conditions and autoimmune disease. Much of its pipeline of drugs is still young, with just one experimental drug so far making its way into early-stage research, being tested out in humans. The series A venture funding in 2018 was led by the investment firm OrbiMed. Other notable investors have included health-tech VC firm F-Prime Capital Partners, Cowen Private Investments and Peter Thiel's Thiel Capital. 26. Tmunity
Round size and year: $135 million in 2018 More about Tmunity: The Philadelphia-based biotech's work is rooted in T cells, which are a component of the human body's disease-fighting immune system. Tmunity is developing genetically-engineered T cells to treat many types of cancer. Its two furthest-along experimental drugs are being tested out in early-stage research in humans. The company's technology, which comes out of the University of Pennsylvania, could also have implications for infectious diseases and autoimmune disease. It is valued at $300 million, according to PitchBook. 25. Beam Therapeutics
Round size and year: $135 million in 2019 More about Beam Therapeutics: The biotech company is using a new type of CRISPR gene editing called "base editing" in hopes of treating diseases in a more precise way. Beam Therapeutics was cofounded by David Liu, Feng Zhang, and Keith Joung, pioneers in the CRISPR field, and has technology licensed from places like Harvard and MIT. The company is valued around $675 million, according to PitchBook. 24. Ambys
Round size and year: $140 million in 2018 More about Ambys: The San Francisco-based biotech company is developing technologies like cell therapy, gene therapies, and more traditional targeted drugs for advanced liver diseases. Its investors include the Japanese pharmaceutical company Takeda and VC Third Rock Ventures. Ambys is valued at $160 million, according to PitchBook. 23. Poseida Therapeutics
Round size and year: $142 million in 2019 More about Poseida Therapeutics: The San Diego-based biopharmaceutical company is developing CAR-T treatments, which harness the body's immune system, with a focus for now on cancers. So far, the company has four such drugs in its pipeline with one drug, P-BMCA-101, having made it to early-stage research in humans for multiple myeloma. Earlier this year the company decided to forgo its IPO plans, instead raising a $142 million series C funding round with Swiss drug giant Novartis as one of the major investors. The company is valued at $568 million, according to PitchBook. 22. BioMotiv
Round size and year: $146 million in 2018 More about BioMotiv: The company aims to speed up the process of bringing new drugs to market, investing in a number of companies with a range of approaches to do just that. BioMotiv also has partnerships with established companies like drugmakers Takeda and Biogen to develop and sell new technologies. The company has raised nearly $270 million, and its valuation is undisclosed, according to PitchBook. 21. Ascentage Pharma
Round size and year: $150 million in 2018 More about Ascentage Pharma: The biopharmaceutical company develops small molecule drugs for cancer, Hepatitis B and age-related illnesses. The company has a number of experimental drugs in the works, including its AT-101 drug, which is mid/late-stage research for chronic lymphocytic leukemia. The company planned to go public on the Hong Kong Stock Exchange in 2018, but it was postponed. 20. Galera Therapeutics
Round size and year: $150 million in 2018 More about Galera Therapeutics: Founded in 2009, the biotech company focuses on therapies to target oral mucositis, a side effect of radiotherapy during cancer treatment that causes severe pain in a patient's mouth. Galera's GC4419 drug is in mid-stage research for oral muscositis, for which it has received "breakthrough therapy" and "fast track" designations from the FDA that help speed along drug development. In August 2018, the company raised $70 million of funding in a series C round led by VC firm Clarus Ventures. The company is valued at around $250 million, according to PitchBook. 19. Freenome
Round size and year: $160 million in 2019 More about Freenome: The San Francisco-based AI genomics company was founded in 2014 and uses routine blood tests with the aim of detecting early signs of cancer. The idea is to detect the disease early before it becomes harder to treat. In July 2019, the company raised $160 million of Series B venture funding in a deal led by Polaris Partners and RA Capital Management. The funds will be used for a validation study and an application would be submitted for its colorectal cancer screening test to the FDA and CMS under the Parallel Review Program, according to PitchBook. 18. Lyell
Round size and year: $179 million in 2019 More about Lyell: The biotech company is focused on treating cancer with cell therapies. Lyell's goal is to develop cell-based immunotherapies for cancer, with a focus on CAR-Ts and solid tumors. It's named after a Scottish geologist who paved the way for Charles Darwin's theory of evolution. Earlier this year, the company raised $179 million of Series B venture funding from Foresite Capital Management, ARCH Venture Partners and Altitude Life Science Ventures. The company's valuation is now at $1.16 billion, according to PitchBook.
Round size and year: $200 million in 2018 More about Helix: The San Francisco-based company is a DNA testing startup that recently launched a new testing kit that assesses your risk of diseases like breast cancer, colon cancer, and high cholesterol. The company is set to rival the better-known DNA testing company 23andMe. The test kit is called GenePrism, and is the result of a year-long collaboration between Helix and clinical diagnostics company PerkinElmer. In May 2019, the company closed two of its four offices and cut an undisclosed number of its staff, Bloomberg News reported. Co-founder Justin Kao told Bloomberg that "we are realigning our business to focus on population health, we are also refocusing our team in support of this goal." Read more: A Silicon Valley startup just launched a DNA-based health test that could be a big competitor to 23andMe 16. Sana Biotechnology
Round size and year: $219 million in 2019 More about Sana Biotechnology: The Seattle-based biotech company develops engineered cells to create medicines to treat various diseases. Founded by Harvard faculty members, Sana also recently licensed new step cell technology from Harvard in hopes of developing cell therapies that don't need to be personalized to an individual patient, also called an "off-the-shelf" approach. The company's founding venture capital firms include ARCH Venture Partners, Flagship Pioneering, and F-Prime Capital, and it is valued at $1.15 billion, according to PitchBook. 15. EdiGene
Round size and year: $227 million in 2017 More about EdiGene: The biotech company develops genome editing technologies to create a variety of therapies for different diseases and cancers. 14. WuXi NextCODE
Round size and year: $200 million in 2018, $240 million in 2017 More about WuXi NextCODE: The US-based company is developing a platform for genomic data. Its investors include Sequoia Capital China and Amgen Ventures. 13. Indigo Agriculture
Round size and year: $250 million in 2018, $203 million in 2017 More about Indigo Agriculture: The Boston-based agricultural tech company uses microbiology and other technology to improve the growth of crops like cotton, wheat, corn, soybeans and rice. According to the company, in 2018 it improved the cotton yield by 14% in commercial fields of West Texas, an improvement from 11% in 2016. The company has a valuation of $3.5 billion with investors from Activant Capital Group, Alaska Permanent Fund, Baillie Gifford & Co. and Flagship Pioneering, according to CB Insights. 12. Celularity
Round size and year: $250 million in 2018 More about Celularity: The New Jersey-based startup, a spinoff from the biotech Celgene, is using stem cells from placentas for various regenerative medicine and cell therapy treatments for cancer. The company currently has six therapies in its pipeline, including two of its furthest-along drugs, which are in early/mid-stage research and intended for multiple myeloma and acute myeloid leukemia. Investors include United Therapeutics, Human Longevity and Celgene. It is valued at $480 million, according to PitchBook. 11. Anthos Therapeutics
Round size and year: $250 million, 2019 More about Anthos Therapeutics: Based in Boston, the biopharmaceutical company is creating targeted therapies for high-risk cardiovascular patients. Earlier this year, the investment company Blackstone Life Sciences and leading pharmaceutical company Novartis launched the company. As part of the deal, Anthos licensed the targeted therapy, MAA868, which helps multiple cardiovascular disorders, like blood clotting. Blackstone funded the full $250 million and will control the company, while Novartis has a minority stake in Anthos, their press release stated. 10. Century Therapeutics
Round size and year: $250 million in 2019 More about Century Therapeutics: The Philadelphia-based biotech is working in a hot new area of cancer research, to develop stem cells that are engineered to kill off cancer tumors. Read more: Companies have poured $8.5 billion into creating a new version of a cutting-edge, highly personalized cancer treatment Century Therapeutics was founded in 2018 by the healthcare investment firm Versant Ventures, and has partnerships with German drugmaker Bayer as well as a stem cell-focused subsidiary of the Japanese multinational Fujifilm Corporation. Century Therapeutics is led by Lalo Flores, a veteran of Johnson & Johnson and Merck, and it has raised about $280 million total, according to PitchBook. 9. Brii Biosciences
Round size and year: $260 million in 2018 More about Brii Biosciences: The biotech is centered around bringing therapeutic innovations to China, where patients haven't always had access to them. It was launched last year with advisors like Alnylam CEO John Maraganore and a board of directors that includes noted biotech VC Robert Nelsen and former Biogen CEO George Scangos. Brii Biosciences has operations in both China and the US and is led by Zhi Hong, a onetime GlaxoSmithKline senior VP. It has raised $260 million from investors like Nelsen's ARCH Venture Partners and Sequoia Capital, according to PitchBook. 8. ADC Therapeutics
Round size and year: $276 million in 2019 More about ADC Therapeutics: The cancer-focused ADC Therapeutics was founded in 2011 and is based in Switzerland. It's led by Chris Martin, who sold his last company, Spirogen, to AstraZeneca in 2013. ADC Therapeutics has raised $551 million at an undisclosed valuation, according to PitchBook. The company was in the early stages of exploring options like an IPO in the fall of 2018, for an estimated value of about $2 billion, Bloomberg News reported then. 7. Viela Bio
Round size and year: $282 million in 2018 More about Viela Bio: The Gaithersburg, Maryland-based biotech makes drugs for autoimmune conditions and diseases of inflammation by targeting certain pathways in the body. Viela Bio has finished late-stage research for its furthest-along product, an experimental medicine for the central nervous system disorder neuromyelitis optica, and plansvto file with the FDA for a review of the medicine. Since it started as a spinoff from AstraZeneca's MedImmune, Viela has raised $357 million at a valuation of $735 million, according to PitchBook. The Jefferies team's prediction, which was made in early August, appears particularly apt: Viela now plans to raise about $150 million in an IPO, according to a SEC filing from late August. 6. Harmony Biosciences
Round size and year: $295 million in 2018 More about Harmony Biosciences: The Pennsylvania-based biotech was founded in 2017 and makes a new medication for narcolepsy. The condition affects up to 200,000 Americans, but "there have been no new advancements to treat the most disruptive symptoms of this disorder in over a decade," according to its Chief Medical Officer Jeffrey Dayno. On Thursday, the FDA approved Harmony Biosciences' narcolepsy treatment, Wakix, making it the first such treatment "not scheduled as a controlled substance" by the US Drug Enforcement Administration, the company said. Harmony Biosciences has raised nearly $500 million, according to PitchBook. 5. Rakuten Medical
Round size and year: $350 million in 2018 More about Rakuten Medical: The San Mateo, California-based biotech is focused on new therapeutic approaches to treating cancer, using a tech platform that it hopes will get the immune system to fight cancer without harming normal, non-cancerous tissue. The biotech is led by the Japanese billionaire Hiroshi Mikitani, who is also founder and CEO of the large Japanese e-commerce retailer Rakuten. Mikitani says he was inspired to fund the cancer research after his father was diagnosed with pancreatic cancer in 2012. Rakuten Medical has raised about $470 million and is valued at $1.15 billion, according to PitchBook. Both Mikitani and Rakuten have invested in Rakuten Medical. 4. Relay Therapeutics
Round size and year: $400 million in 2018 More about Relay Therapeutics: The Cambridge, Massachusetts-based biotech was founded with a focus on protein motion, with the intent of developing better drugs for diseases like cancer. It has raised about $520 million from investors like SoftBank, Casdin Capital and GV, Google's $4.5 billion venture arm. Read: A top investor who cashed in on recent $8 billion and $5 billion biotech takeovers earlier this year told us he's looking beyond the 'sexy' parts of healthcare as he places his next bets 3. Zymergen
Round size and year: $407 million in 2018 More about Zymergen: The Silicon Valley-based startup is using synthetic biology to make completely new products across sectors like pharmaceuticals, agriculture, electronics and personal care. The idea is to make manufacturing cheaper, faster and more environmentally sustainable by grounding it in cells, versus traditional, petrochemical-based routes. One of Zymergen's new projects is a safe, nontoxic insect repellant, CEO Joshua Hoffman told Business Insider late last year. Read more: A Silicon Valley startup with 26 patents under its belt just raised $400 million from SoftBank and Goldman Sachs to make materials from living things To that aim, the startup has raised nearly $600 million, and is valued at nearly $1 billion, according to PitchBook. 2. Vir
Round size and year: $416 million in 2018 More about Vir: Founded by Robert Nelsen, who Forbes has called "biotech's top venture capitalist," the San Francisco, California-based Vir has raised $566 million at an undisclosed valuation, according to PitchBook. Led by former Biogen CEO George Scangos, Vir is working to develop drugs for chronic infectious diseases like hepatitis B and HIV, respiratory diseases like the flu, and infections that patients get while in the hospital. On Tuesday, Vir filed paperwork with the US Securities and Exchange Commission to go public. 1. Intarcia Therapeutics
Round size and year: $615 million in 2017 More about Intarcia: The Boston, Massachusetts-based biotech is developing drugs for chronic diseases like obesity and HIV. The biotech's furthest-along product is an implant for type 2 diabetes that's intended to reduce how often patients need injections. Intarcia is valued at about $4.1 billion, according to PitchBook, with investors including Fidelity, New Enterprise Associates, and the Bill & Melinda Gates Foundation. This story was first published in mid-August. It has been updated.
More like this (3)
UBS just shared the 4 biotech stocks investors should buy now — including 2 that could soar more than 50%
Summary List Placement 2021 is shaping up to be a critical year for the biotech industry....Summary List Placement 2021 is shaping up to be a critical year for the biotech industry. Drugmakers are racing to develop treatments and vaccines that will help combat the coronavirus pandemic. While that work progresses, biotech companies focused on finding treatments for conditions like Duchenne muscular dystrophy, cystic fibrosis, and Alzheimer's disease are carrying on their work with pivotal data or approvals expected in...
Trump just received Regeneron's experimental COVID-19 treatment. Here's the inside story of the biotech and its 2 billionaire founders. (REGN)
Summary List Placement One of our best hopes for fighting the coronavirus pandemic may have...Summary List Placement One of our best hopes for fighting the coronavirus pandemic may have started with a signed napkin in 1988. On that napkin, a neurologist named Leonard Schleifer scribbled the basics of a deal to start a new biotechnology company. His dinner companion, George Sing, a banker at Merrill Lynch, agreed to give Schleifer a million dollars in funding to launch...
The top 20 most valuable venture-backed AI companies, including Palantir, UiPath, and Databricks — valued at $120 billion total (UBER, GOOG)
A list of the 20 most valuable venture-backed companies in artificial intelligence boasts a combined valuation...A list of the 20 most valuable venture-backed companies in artificial intelligence boasts a combined valuation of some $120 billion. Most of the list are privately-held startups; some of them — namely Waymo and Uber Advanced Technology Group — are subsidiaries of much larger companies, but that are said to be eyeing IPOs of their own. Investment remains robust despite an uncertain economy, a...